Immunovant Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
14.55
0.53
(3.78%)
Volume:
1,046,711
52 week range:
12.72 - 34.47
Market Cap:
2.471B
Company Description:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.